Results 1 to 10 of about 21,590 (76)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit, Yeamin Huh, Martin E. Dowty, Anna Plotka, Alexandre Lejeune, Hindu Kalluru, Brian Hee   +6 more
wiley   +1 more source

Developing the Inpatient Mental Health Pharmaceutical Assessment and Care Tool (IMPACT) for use by UK mental health pharmacy teams—a modified Delphi study

British Journal of Clinical Pharmacology, EarlyView.
Aims To develop an evidence‐ and consensus‐based patient prioritization tool for use by UK mental health inpatient pharmacy teams. Methods A modified‐Delphi technique was used to obtain experts' agreement on the content, design and practical use of the patient prioritization tool.
Fatima Q. Alshaikhmubarak, Richard N. Keers, Petra Brown, Penny J. Lewis   +3 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Yingxue Chen, Renli Teng, Attila Szanto, Apoorva Kapopara, Rajat Bannerji, Julien Ogier, Devalingam Mahalingam   +6 more
wiley   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fruquintinib (FRUZAQLATM) is a highly selective tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3). Two Phase 1, open‐label, single‐dose studies investigated the impact of hepatic or renal impairment on the pharmacokinetics and tolerability of fruquintinib.
Martha Gonzalez, Zhao Yang, William Schelman, Thomas C. Marbury, Juan C. Rondon, William Smith, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +8 more
wiley   +1 more source

Unexpected Perseverance in Tinea Corporis – Special Mutations Found in Trichophyton indotineae Dermatomycosis

JEADV Clinical Practice, EarlyView.
ABSTRACT We hereby present the case of a patient with tinea incognita, who had received treatment with glucocorticosteroids and antibiotics for several months. Further diagnostic testing identified Trichophyton indotineae as the pathogen causing tinea corporis and cruris. The Erg1 gene encoding squalene epoxidase showed wild‐type information; therefore,
Deborah M. Gregersen, Nadine Berstecher, Anke Burmester, Jörg Tittelbach, Cornelia Wiegand   +4 more
wiley   +1 more source

Infectious Morbidity During Pediatric Acute Myeloid Leukemia Chemotherapy in a High‐Income Country: A 15‐Year Population‐Based Overview

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Infection causes significant morbidity and mortality in pediatric acute myeloid leukemia (pAML). This study describes the incidence and risk factors of bloodstream infection (BSI) and invasive fungal infection (IFI) in pAML. Methods A retrospective chart review was performed of patients treated according to the ANLL‐97/AML‐12 (N =
Emily R. Schwartz, Kim Klein, Birgit I. Lissenberg‐Witte, Tom F. W. Wolfs, Valérie de Haas, Bianca Goemans, Natasja Dors, Marry M. van den Heuvel‐Eibrink, Rutger R. G. Knops, Wim J. E. Tissing, Birgitta A. Versluys, C. Michel Zwaan, Raphaële R. L. van Litsenburg, Gertjan J. L. Kaspers   +13 more
wiley   +1 more source